Source-grounded facts extracted from CLOROX CO /DE/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Nina Barton was appointed as Executive Vice President and Chief Growth & Strategy Officer at CLOROX CO /DE/.
“Nina Barton, formerly Executive Vice President and Group President – Care & Connection, was appointed Executive Vice President and Chief Growth & Strategy Officer, effective June 17, 2026.”
Linda Rendle departed as Chair of the Board and Chief Executive Officer at CLOROX CO /DE/.
“On May 26, 2026, Linda Rendle, Chair of the Board of Directors (the “Board”) and Chief Executive Officer (“CEO”) of The Clorox Company (the “Company”), asked the Board to initiate a CEO search process, as she has made the decision to step down for health reasons.”
CLOROX CO /DE/ reported the third quarter of fiscal year 2026, which ended March 31, 2026 results: revenue $1.67 billion, EPS $1.54. Guidance reaffirmed.
“2026 Summary Following is a summary of key results for the third quarter. All comparisons are with the third quarter of fiscal year 2025 unless otherwise stated. • Net sales of $1.67 billion were flat versus the year-ago quarter. Organic sales 1 decreased 1%. • Gross margin decreased 140 basis points to 43.2% from 44.6% in the year-ago quarter, primarily driven by”
CLOROX CO /DE/ entered into 364-Day Revolving Credit Agreement with JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association valued at $1,000,000,000 (effective 2026-03-06).
“On March 6, 2026, in connection with the purchase of all of the issued and outstanding membership interests of GOJO Industries, Inc. (“GOJO”), maker of PURELL® (the “Gojo Acquisition”), pursuant to a membership interest purchase agreement (the “Acquisition Agreement”), by and among The Clorox Company (the “Company”), GOJO Industries Holdings, Inc., GOJO and certain shareholders, the Company entered into (i) a $1,000,000,000 364-day revolving credit agreement (the “364-Day Revolving Credit Agreement”) among JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association, as administrative agents and lenders, and the other agents and lenders party thereto”
CLOROX CO /DE/ incurred term loan of $1,250,000,000 with JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association maturing March 5, 2027.
“a $1,250,000,000 term credit agreement (the "Delayed Draw Term Credit Agreement"”
CLOROX CO /DE/ incurred revolving credit of $1,000,000,000 with JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association at Term SOFR Rate plus an applicable margin that fluctuates depending on the Credit maturing March 5, 2027.
“the Company entered into (i) a $1,000,000,000 364-day revolving credit agreement”
CLOROX CO /DE/: Amended and restated bylaws to implement a cure process for deficiencies in director nomination notices submitted by shareholders. The Company will notify shareholders of deficiencies, allowing them an opportunity to cure within a specified time period (effective 2025-05-19).
“The Board of Directors of The Clorox Company (the “Company”) amended and restated the Company’s bylaws (the “Bylaws”), effective May 19, 2025. The amendments implement a cure process for certain deficiencies in director nomination notices submitted by shareholders. For nomination notices received by the Company within the time period specified in the Bylaws, the Company will notify shareholders of deficiencies in the notice and there will be an opportunity to cure such deficiencies within the time period specified.”
Gina Boswell was elected as Director at CLOROX CO /DE/.
“On May 11, 2025, the Board of Directors (the “Board”) of The Clorox Company (the “Company”) elected Gina Boswell to the Board, effective May 19, 2025.”
CLOROX CO /DE/ incurred revolving credit of $1,200,000,000 with JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association, as administrative agents, and lenders maturing five-year.
“On March 25, 2025, The Clorox Company (“the Company”) entered into a $1,200,000,000 five-year unsecured revolving credit agreement (the “Agreement”) among JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association, as administrative agents, and lenders, and the other agents and lenders party thereto (the “Lenders”).”
Luc Bellet was appointed as Executive Vice President – Chief Financial Officer at CLOROX CO /DE/.
“On January 23, 2025, the Management Development and Compensation Committee (the “MDCC”) of the Board of Directors of the Company appointed Luc Bellet, age 46, to be Executive Vice President – Chief Financial Officer, effective April 1, 2025.”
Kevin Jacobsen departed as Executive Vice President – Chief Financial Officer at CLOROX CO /DE/.
“On January 23, 2025, Kevin Jacobsen, Executive Vice President – Chief Financial Officer of The Clorox Company (the “Company”), provided notice of his intention to retire from the Company effective April 1, 2025”
CLOROX CO /DE/ reported third quarter ended March 31, 2024 results: revenue $1.81 billion, EPS ($0.41) per diluted share.
“20, 2024 divestiture of the company's Argentina business and all comparisons are with the third quarter of fiscal year 2023 unless otherwise stated. • Net sales decreased 5% to $1.81 billion compared to a 6% net sales increase in the year-ago quarter. The decrease was driven largely by lower volume from temporary distribution losses resulting from the widescale”
CLOROX CO /DE/ reported the second quarter of fiscal year 2024, which ended Dec. 31, 2023 results: EPS 75 cents.
“On February 1, 2024 , The Clorox Company issued a press release announcing its financial results for its second quarter ended December 31, 2023.”
CLOROX CO /DE/ shareholders approved Ratification of the selection of Ernst & Young LLP as the Company's independent auditor for 2024 at the 2023-11-15 meeting.
“Ratification of the selection of Ernst & Young LLP as the Company's independent auditor for 2024. Number of Votes For Against Abstain Broker Non-Votes 100,088,352 4,036,422 261,703 0”
CLOROX CO /DE/ shareholders approved Advisory Vote on the Frequency of Future Advisory Votes to Approve Executive Compensation at the 2023-11-15 meeting.
“Advisory Vote on the Frequency of Future Advisory Votes to Approve Executive Compensation: Number of Votes One Year Two Years Three Years Abstain Broker Non-Votes 84,325,421 189,088 1,408,855 345,134 18,117,979”
CLOROX CO /DE/ shareholders approved Advisory Vote on the Approval of Named Executive Officers Compensation at the 2023-11-15 meeting.
“Advisory Vote on the Approval of Named Executive Officers Compensation: Number of Votes For Against Abstain Broker Non-Votes 80,442,142 5,304,739 521,616 18,117,979”
CLOROX CO /DE/ shareholders approved Election of Directors at the 2023-11-15 meeting.
“The shareholders (1) elected all of the Company's nominees for director;”
CLOROX CO /DE/ reported the first quarter of fiscal year 2024, which ended Sept. 30, 2023 results: revenue $1.4 billion, EPS 17 cents.
“by the impact of the previously announced cyberattack. All comparisons are with the first quarter of fiscal year 2023 unless otherwise stated. • Net sales decreased 20% to $1.4 billion compared to a 4% net sales decrease in the year-ago quarter. The decrease was driven largely by lower volume resulting from the cyberattack, partially offset by favorable price”
CLOROX CO /DE/ reported first fiscal quarter of 2024 / first quarter of fiscal 2024 / three months ended Sept. 30, 2023 results: revenue Net sales are expected to decrease by 28% to 23% from the year-ago quarter, EPS Diluted net earnings per share (diluted EPS) is expected to be between a loss of $0.75 to a loss of $0.35.
“30, 2023, as well as an operations update following the previously announced cybersecurity attack that impacted the Company’s business. · Net sales are expected to decrease by 28% to 23% from the year-ago quarter. Organic sales are now expected to decrease by 26% to 21% for the quarter, compared to the Company’s prior expectations of mid-single-digits”
CLOROX CO /DE/ reported financial results for the fourth quarter and fiscal year ended June 30, 2023.
“The Clorox Company issued a press release announcing its financial results for its fourth quarter and fiscal year ended June 30, 2023.”
Dan Dahlgren was appointed as Interim leader of Care & Connection group at CLOROX CO /DE/.
“The Company announced that Dan Dahlgren, a long-time Clorox executive who retired last year, will return to the Company to provide interim leadership to the Company’s Care & Connection group.”
Rebecca Dunphey resigned as Group President – Care & Connection at CLOROX CO /DE/.
“On July 24, 2023, Rebecca Dunphey, Group President – Care & Connection of The Clorox Company (the “Company”), provided notice of her intention to resign from the Company effective August 11, 2023.”
CLOROX CO /DE/: Amended and restated bylaws to add procedural requirements for universal proxy rules, change proxy card color, add nominee disclosure and interview requirements, and add emergency provisions (effective 2023-05-22).
“The Board of Directors (the “Board”) of The Clorox Company (the “Company”) amended and restated the Company’s bylaws (the “Bylaws”), effective May 22, 2023, in connection with the effectiveness of new Securities and Exchange Commission (the “SEC”) rules regarding universal proxy cards and a periodic review of the Bylaws.”
CLOROX CO /DE/ reported third quarter ended March 31, 2023 results: revenue $1.91 billion, EPS (a noncash impairment charge of $445 million ($362 million after tax or $2.92) ...). Guidance raised.
“Summary Following is a summary of key third-quarter results. All comparisons are with the third quarter of fiscal year 2022 unless otherwise stated. • Net sales increased 6% to $1.91 billion compared to a 2% net sales increase in the year-ago quarter. The net sales increase was driven largely by favorable price mix, partially offset by lower volume. Organic sales 1”
CLOROX CO /DE/ reported the second quarter of fiscal year 2023, which ended Dec. 31, 2022 results: revenue $1.72 billion, EPS 80 cents.
“Following is a summary of key second-quarter results. All comparisons are with the second quarter of fiscal year 2022 unless otherwise stated. • Net sales increased 1% to $1.72 billion compared to an 8% net sales decrease in the year-ago quarter. The net sales increase was driven largely by favorable price mix, partially offset by lower volume . Organic sales 1”
CLOROX CO /DE/ shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending June 30, 2023 at the 2022-11-16 meeting.
“3. The Company’s shareholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023. Number of Votes For Against Abstain Broker Non-Votes 102,642,634 1,870,724 318,740 0”
CLOROX CO /DE/ shareholders approved Advisory vote to approve compensation of named executive officers at the 2022-11-16 meeting.
“2. The Company’s shareholders voted for (on an advisory basis) the approval of the compensation of the Company’s named executive officers. Number of Votes For Against Abstain Broker Non-Votes 80,870,158 5,199,569 539,543 18,222,827”
CLOROX CO /DE/ shareholders approved Election of Directors at the 2022-11-16 meeting.
“1. The Company’s shareholders elected the following directors to each serve until the next Annual Meeting of Shareholders or until a successor is duly elected and qualified. Number of Votes For Against Abstain Broker Non-Votes Amy L. Banse 85,257,601 1,090,707 260,962 18,222,827 Julia Denman 85,663,547 679,455 266,267 18,222,827 Spencer C. Fleischer 84,833,382 1,491,959 283,930 18,222,827 Esther Lee 85,460,628 888,455 260,187 18,222,827 A.D. David Mackay 85,544,613 790,520 274,137 18,222,827 Paul Parker 85,692,013 641,810 275,448 18,222,827 Stephanie Plaines 85,600,327 743,060 265,883 18,222,827 Linda Rendle 85,542,167 802,236 264,867 18,222,827 Matthew J. Shattock 84,014,161 2,326,236 268,874 18,222,827 Kathryn Tesija 85,386,553 959,875 262,842 18,222,827 Russell J. Weiner 85,520,082 803,127 286,061 18,222,827 Christopher J. Williams 85,277,028 1,054,292 277,951 18,222,827”
CLOROX CO /DE/ reported first quarter of fiscal year 2023, which ended Sept. 30, 2022 results: revenue $1.74 billion, EPS 68 cents. Guidance reaffirmed.
“The Clorox Company (NYSE: CLX) today reported results for the first quarter of fiscal year 2023, which ended Sept. 30, 2022. First-Quarter Fiscal Year 2023 Summary Following is a summary of key first-quarter results. All comparisons are with the first quarter of fiscal year 2022 unless otherwise stated. • Net sales decreased 4% to $1.74 billion compared to a 6% net sales decrease in the year-ago quarter. The net sales decrease was driven largely by lower volume, partially offset by favorable price mix. Organic sales 1 were down 2%. The three-year average growth rate for net sales was up 5%. • Gross margin decreased 110 basis points to 36% from 37.1% in the year-ago quarter, due to higher manufacturing and logistics costs, higher commodity costs, and lower volume, partially offset by the benefits of pricing and cost savings initiatives. • Diluted net earnings per share (diluted EPS) decreased 40% to 68 cents from $1.14 in the year-ago quarter.”
Stephanie Plaines was elected as Director at CLOROX CO /DE/.
“elected Julia (Charter) Denman and Stephanie Plaines to the Board, each effective as of May 16, 2022.”
Julia Denman was elected as Director at CLOROX CO /DE/.
“elected Julia (Charter) Denman and Stephanie Plaines to the Board, each effective as of May 16, 2022.”
Stacey Grier changed role as Executive Vice President – Chief Growth & Strategy Officer at CLOROX CO /DE/.
“Stacey Grier, currently Senior Vice President – Chief Marketing and Strategy Officer, is being promoted to the role of Executive Vice President – Chief Growth & Strategy Officer, effective March 14, 2022.”
Tony Matta departed as Executive Vice President – Chief Growth Officer at CLOROX CO /DE/.
“Tony Matta, Executive Vice President – Chief Growth Officer of the Company, would be leaving the Company, effective March 11, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.